ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Arcutis Biotherapeutics, Inc. ?
1
With a growth in Net Sales of 59.33%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 12 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 39.31 MM
- ROCE(HY) Highest at 15.86%
- PRE-TAX PROFIT(Q) At USD 15.14 MM has Grown at 197.43%
2
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating performance in long term as well as near term
- Along with generating 79.11% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Arcutis Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Arcutis Biotherapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Arcutis Biotherapeutics, Inc.
79.11%
3.96
59.45%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
227.56%
EBIT Growth (5y)
13.82%
EBIT to Interest (avg)
-54.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.65
Tax Ratio
0.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.91
EV to EBIT
-206.30
EV to EBITDA
-376.09
EV to Capital Employed
32.70
EV to Sales
6.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-15.85%
ROE (Latest)
-8.67%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 39.31 MM
ROCE(HY)
Highest at 15.86%
PRE-TAX PROFIT(Q)
At USD 15.14 MM has Grown at 197.43%
NET PROFIT(Q)
At USD 15.01 MM has Grown at 194.48%
RAW MATERIAL COST(Y)
Fallen by -0.86% (YoY
NET SALES(Q)
Highest at USD 129.86 MM
-4What is not working for the Company
INTEREST(HY)
At USD 7.77 MM has Grown at 29.33%
Here's what is working for Arcutis Biotherapeutics, Inc.
Operating Cash Flow
Highest at USD 39.31 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 129.86 MM has Grown at 59.33%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 15.14 MM has Grown at 197.43%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 15.01 MM has Grown at 194.48%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 129.86 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -0.86% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Arcutis Biotherapeutics, Inc.
Interest
At USD 7.77 MM has Grown at 29.33%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
